{"log_id": 2236411606348354437, "direction": 0, "words_result_num": 45, "words_result": [{"probability": {"variance": 0.010125, "average": 0.960294, "min": 0.457386}, "location": {"width": 811, "top": 169, "height": 45, "left": 201}, "words": "效浓度(EC和EC)分别是0.005到16.0uM和10.05到>100μM扎那米韦抑制流感病"}, {"probability": {"variance": 0.015073, "average": 0.954708, "min": 0.503667}, "location": {"width": 422, "top": 206, "height": 35, "left": 203}, "words": "母细胞与流感病每在人体复制的关系尚未建立"}, {"probability": {"variance": 3e-06, "average": 0.998401, "min": 0.995871}, "location": {"width": 66, "top": 268, "height": 24, "left": 202}, "words": "耐药性"}, {"probability": {"variance": 0.007303, "average": 0.976065, "min": 0.47233}, "location": {"width": 810, "top": 279, "height": 44, "left": 203}, "words": "通过在递增药物浓度的环境中多次传代病,可以选定对扎那米韦敏感性下降的流感病毒"}, {"probability": {"variance": 0.002893, "average": 0.979389, "min": 0.725071}, "location": {"width": 808, "top": 308, "height": 45, "left": 206}, "words": "对这些白细胞培养的病毒进行基因分析,对扎那米韦敏感性的下降与基因突变而导致的神"}, {"probability": {"variance": 0.009669, "average": 0.963849, "min": 0.437691}, "location": {"width": 808, "top": 337, "height": 44, "left": 204}, "words": "经氨酸酶或红血球凝聚或两者的氨基酸改变有关。由细胞培养选定的已发生神经氨酸酶"}, {"probability": {"variance": 0.011967, "average": 0.959175, "min": 0.48882}, "location": {"width": 811, "top": 366, "height": 42, "left": 206}, "words": "氨基酸替换的耐药性突变包括E119G/A/D和IR292K.由细胞培养选定的已发生红血球凝聚"}, {"probability": {"variance": 0.009887, "average": 0.932223, "min": 0.538357}, "location": {"width": 730, "top": 395, "height": 42, "left": 205}, "words": "素替代的突变包括K68R,G75E,E114K,NI45S,S165N,S186F,N199S,和K222"}, {"probability": {"variance": 0.004646, "average": 0.976196, "min": 0.697845}, "location": {"width": 810, "top": 421, "height": 44, "left": 205}, "words": "在感染了流感B病毒的免疫低下病人中,使用扎那米书研究性喷雾溶液治疗2周后有病毒"}, {"probability": {"variance": 0.004151, "average": 0.979557, "min": 0.674114}, "location": {"width": 822, "top": 448, "height": 43, "left": 205}, "words": "变异体出现。对这些变异进行分析发现一个红血球凝聚素的替换(T198T)导致人体细胞受"}, {"probability": {"variance": 0.000427, "average": 0.987348, "min": 0.891974}, "location": {"width": 816, "top": 476, "height": 43, "left": 204}, "words": "体亲和力的下降,神经氨酸酶活性位点(R152K)的替换将该酶对扎那米韦的活性降低了100"}, {"probability": {"variance": 0.006149, "average": 0.96233, "min": 0.715744}, "location": {"width": 628, "top": 508, "height": 39, "left": 205}, "words": "倍,能表征扎那米韦在临床使用中会出现耐药性危险的信息还很缺乏"}, {"probability": {"variance": 0, "average": 0.999575, "min": 0.999013}, "location": {"width": 105, "top": 573, "height": 25, "left": 208}, "words": "交叉耐药性"}, {"probability": {"variance": 0.008496, "average": 0.977258, "min": 0.418227}, "location": {"width": 799, "top": 585, "height": 43, "left": 208}, "words": "在某些扎那米韦耐药和奥司他耐药的由细胞培养的流感病毒突变体中已发现交义耐药性"}, {"probability": {"variance": 0.010947, "average": 0.95816, "min": 0.400905}, "location": {"width": 811, "top": 614, "height": 42, "left": 210}, "words": "不过某些细胞培养的扎那米韦耐药突变体如E119G/A/D和R292K,与奥塞米耐药的临床隔"}, {"probability": {"variance": 0.021969, "average": 0.959085, "min": 0.178173}, "location": {"width": 815, "top": 643, "height": 40, "left": 207}, "words": "离群一样突变发生在神经氨酸酶相同的氨基酸位置,如E19 and R292K.还没有进行临床"}, {"probability": {"variance": 0.001517, "average": 0.984716, "min": 0.858259}, "location": {"width": 341, "top": 680, "height": 30, "left": 209}, "words": "使用会引起交义耐药风险的评估研究"}, {"probability": {"variance": 0, "average": 0.999353, "min": 0.999018}, "location": {"width": 100, "top": 737, "height": 24, "left": 209}, "words": "致突变作用"}, {"probability": {"variance": 0.008343, "average": 0.974808, "min": 0.414056}, "location": {"width": 818, "top": 749, "height": 43, "left": 210}, "words": "扎那米在细突变试验、小鼠淋巴细胞人染色体试验、人外周血染色体试验、小鼠骨髓微核细胞"}, {"probability": {"variance": 0.019997, "average": 0.927633, "min": 0.612025}, "location": {"width": 105, "top": 793, "height": 23, "left": 221}, "words": "式验结果阴性"}, {"probability": {"variance": 1e-06, "average": 0.998355, "min": 0.997502}, "location": {"width": 84, "top": 849, "height": 23, "left": 212}, "words": "生殖毒性"}, {"probability": {"variance": 0.008522, "average": 0.970994, "min": 0.409463}, "location": {"width": 806, "top": 861, "height": 40, "left": 212}, "words": "在雄性大鼠(交配前10周、交配、怀孕/哺乳期期和断奶短期)、雌性大鼠(交配前3"}, {"probability": {"variance": 0.014274, "average": 0.94513, "min": 0.413075}, "location": {"width": 820, "top": 888, "height": 42, "left": 211}, "words": "周、直到妊娠的19天或产后21天)静注1、9、90mg/kgd扎那米,未见对大鼠交配和生"}, {"probability": {"variance": 0.006891, "average": 0.967257, "min": 0.626294}, "location": {"width": 817, "top": 915, "height": 42, "left": 214}, "words": "育力的影响,对大鼠精子未见影响。对F1代雌性小鼠的繁殖能力未见影响。大鼠亚急性毒性"}, {"probability": {"variance": 0.018912, "average": 0.924214, "min": 0.382462}, "location": {"width": 780, "top": 944, "height": 42, "left": 213}, "words": "研究中,静脉注射90mg/kgd,AC在142199 mcg.hr/m(大于人临床暴路量的300倍"}, {"probability": {"variance": 0.005488, "average": 0.97575, "min": 0.528907}, "location": {"width": 810, "top": 971, "height": 41, "left": 213}, "words": "在大鼠(从妊娠第6天至第15天给药)和家兔(从妊娠第7火至第19天给药)中使用相"}, {"probability": {"variance": 0.013828, "average": 0.948093, "min": 0.564389}, "location": {"width": 809, "top": 998, "height": 43, "left": 212}, "words": "同的静脉给药剂量进行胚胎胎儿发育研究(1、9和90mg/kg/口)。在大鼠中进行产前和产"}, {"probability": {"variance": 0.007154, "average": 0.967278, "min": 0.621173}, "location": {"width": 824, "top": 1024, "height": 44, "left": 210}, "words": "后发育研究(从妊娠第16天开始给药直到幼崽第21天至23天)。在妊娠大鼠或家兔及其胎"}, {"probability": {"variance": 0.007509, "average": 0.963401, "min": 0.681149}, "location": {"width": 379, "top": 1061, "height": 33, "left": 213}, "words": "儿中没有发现畸形、母体毒性或胚治毒性"}, {"probability": {"variance": 0.001885, "average": 0.985358, "min": 0.729737}, "location": {"width": 793, "top": 1080, "height": 42, "left": 213}, "words": "在大鼠中进行了另一项胚胎/胎儿研究,在妊娠的第7天至17天使用扎那米韦皮下给药"}, {"probability": {"variance": 0.008908, "average": 0.958584, "min": 0.489127}, "location": {"width": 819, "top": 1107, "height": 42, "left": 215}, "words": "每大3次,剂量为1、9或80mg/kg。本研究中暴露的后代各种微小骨恪改变和变化发生率"}, {"probability": {"variance": 0.014931, "average": 0.946943, "min": 0.365017}, "location": {"width": 809, "top": 1135, "height": 42, "left": 213}, "words": "升高。根据ALC测量,80mg/kg剂量产生的暴露量超过人体拟定临床剂量暴露的1000倍"}, {"probability": {"variance": 0.000862, "average": 0.98877, "min": 0.82611}, "location": {"width": 808, "top": 1162, "height": 42, "left": 213}, "words": "但在大部分情况下,各种骨骼改变或变异的个体发生率仍在研究种系历史背景发生率以内"}, {"probability": {"variance": 0.00428, "average": 0.973444, "min": 0.63415}, "location": {"width": 813, "top": 1189, "height": 44, "left": 213}, "words": "扎那米韦透过大鼠和家兔的胎盘。在这些动物中,胎儿血液中扎那米韦的浓度明显低于母"}, {"probability": {"variance": 1.1e-05, "average": 0.99707, "min": 0.99236}, "location": {"width": 146, "top": 1233, "height": 25, "left": 216}, "words": "体血液中的浓度"}, {"probability": {"variance": 0.010973, "average": 0.963518, "min": 0.477614}, "location": {"width": 822, "top": 1269, "height": 43, "left": 212}, "words": "致癌性:大鼠、小鼠吸入粉末2年的研究中,扎那米与对照组相比无明显的统计学上的肿"}, {"probability": {"variance": 0.012366, "average": 0.944882, "min": 0.49547}, "location": {"width": 795, "top": 1299, "height": 39, "left": 214}, "words": "瘤诱导增加。以人临床剂量的AUC计算,在大鼠、小鼠的最大每日暴露量人约为人临床剂量23"}, {"probability": {"variance": 0.022148, "average": 0.934237, "min": 0.522201}, "location": {"width": 133, "top": 1339, "height": 24, "left": 215}, "words": "25和20-22倍"}, {"probability": {"variance": 3e-06, "average": 0.998725, "min": 0.994879}, "location": {"width": 136, "top": 1389, "height": 24, "left": 223}, "words": "【药代动力学】"}, {"probability": {"variance": 5.5e-05, "average": 0.996841, "min": 0.956396}, "location": {"width": 811, "top": 1414, "height": 41, "left": 217}, "words": "吸收和生物利用度:经口吸入扎那米韦的药代动力学研究表明接近4%到17%的吸入量被"}, {"probability": {"variance": 0.007422, "average": 0.975545, "min": 0.463195}, "location": {"width": 815, "top": 1443, "height": 38, "left": 220}, "words": "全身吸收。给药10mg后的1到2小时内的血清浓度峰值范围为17到142ng/mLa血清浓"}, {"probability": {"variance": 0.007115, "average": 0.967513, "min": 0.563676}, "location": {"width": 538, "top": 1476, "height": 33, "left": 217}, "words": "度比时间的曲线下面积(AUC)为111到1364ngh/mL"}, {"probability": {"variance": 0.00027, "average": 0.992118, "min": 0.920983}, "location": {"width": 430, "top": 1515, "height": 37, "left": 218}, "words": "分布:扎那米韦的血浆蛋白结合率较低(<10%"}, {"probability": {"variance": 0.011809, "average": 0.967915, "min": 0.431641}, "location": {"width": 647, "top": 1552, "height": 38, "left": 219}, "words": "代谢:扎那米韦以药的形式从肾脏排泄。在人体内未检测到代谢产物"}, {"probability": {"variance": 0.00068, "average": 0.957337, "min": 0.934921}, "location": {"width": 73, "top": 1616, "height": 20, "left": 586}, "words": " Page 8 of"}], "language": 3}